83 results about "Hepatic Cancers" patented technology

The invention discloses a liver enhanced CT (Computed Tomography) feature extraction and fusion method based on a vascular topological structure, which relates to the technical field of medical image processing, and comprises the following steps: acquiring a liver enhanced CT image, preprocessing the liver enhanced CT image, rigidly registering the liver enhanced CT image and then taking the same as input, and acquiring a time feature vector based on a time feature extraction model; partitioning the registered liver enhanced CT image according to a vascular topological structure to obtain a plurality of liver partitioned images; dividing the time feature vector according to the plurality of liver partition images to obtain a partition feature vector corresponding to each liver partition image, taking the partition feature vectors as input, and performing spatial feature extraction and fusion based on a spatial feature extraction model to obtain a time-spatial feature vector; and calculating the time-space feature vector to obtain a classification result, and the like. According to the method, finer time and space feature extraction fusion of the liver enhanced CT image is realized, and the liver cancer detection and classification precision is improved.

The invention relates to the technical field of medical image processing, in particular to a liver cancer intervention auxiliary system. According to the method, the boundary structure and curvature change of the liver region can be extracted from multi-source images such as MRI, CT and enhanced CT through cooperative processing of multi-modal images, and candidate path segments are constructed step by step by utilizing continuity and direction stability of a boundary turning region; sorting identification is carried out on the candidate path segments in combination with image parameters such as gray distribution, texture features and background contrast, path segment quality levels based on multiple image characteristics are established, and path areas with multi-modal parameter advantages in the image are enhanced and displayed by evaluating response distribution of the sorting levels and carrying out weight adjustment, so that the image quality is improved. And finally, the path information after transparency adjustment or edge enhancement is superposed in the original image frame, so that the image presents a clearer path structure and spatial distribution, and the visual perception capability of a doctor on the direction of the intervention path is improved.

The invention discloses application of ADRA1A as an anti-liver cancer diagnosis and treatment target. The invention provides application of an ADRA1A gene or protein in preparation of a product for diagnosing and / or treating liver cancer. The diagnosis comprises diagnosis for distinguishing liver cancer patients from healthy people, liver cancer staging and grading diagnosis, liver cancer malignancy degree diagnosis, liver cancer lymph node metastasis diagnosis, liver cancer vascular invasion and liver cancer prognosis diagnosis. According to the application disclosed by the invention, the effect of the neurotransmitter receptors in liver cancer development is researched, large-sample liver cancer sequencing data analysis is taken as an entry point, the influence of various neurotransmitter receptors on liver cancer prognosis is comprehensively analyzed, and the receptor subtype gene ADRA1A which remarkably influences liver cancer prognosis and has the most clinical transformation potential is screened out from the analysis point. The invention provides a new thought and target for clinical diagnosis and treatment of liver cancer.

This invention relates to the field of medical device technology, specifically to an auxiliary device for hepatic artery angiography in interventional treatment of liver cancer. The device includes a fixed carrier with a flexible base and several supporting components. Each supporting component includes several arc-shaped connecting strips hinged together. Several adjustment boxes are installed on both sides of the flexible base, each containing an adjustment component. Each adjustment component includes a drive element with a bidirectional lead screw fixed to it. Nut seats are threaded to both ends of the bidirectional lead screw, and sliders are fixed to the nut seats. Traction cables are fixedly connected to the sliders, and the traction cables are hinged to the nodes of the arc-shaped connecting strips. The drive element is signal-connected to a control module. The control module controls the drive element to rotate the bidirectional lead screw forward and backward according to preset patient body shape parameters. This causes the sliders to slide through the nut seats, thereby causing the traction cables to pull the nodes of the arc-shaped connecting strips. This invention achieves multi-dimensional safety protection through mechanical structure linkage and sensor feedback, reducing surgical field interference.

Abstract The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 2020220128 20 Aug 2020

The invention discloses a mouse liver cancer cell line with a high lung metastasis characteristic as well as a construction method and application thereof, and belongs to the technical field of biology and oncology. The cell is preserved in China Center for Type Culture Collection on February 4, 2026, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202621. The PNV-LM3 cell line provided by the invention is constructed by combining a PTEN KO and NRAS G12V mutated hydrodynamic tail vein injection model with tail vein injection in-vivo domestication, a mouse liver cancer model is successfully induced to generate lung metastasis, and the lung metastasis tendency of the cell line is greatly enhanced. Compared with a traditional Hepa1-6 cell line, the PNV-LM3 cell line has the advantages that the lung metastasis process of the liver cancer is more accurately and efficiently reproduced, and a more real experimental platform is provided for research of a liver cancer metastasis mechanism.

This invention discloses a sophoridine tricyclic derivative or its pharmaceutical salt, with the following general structural formula: R1 is selected from hydrogen, C1-C20 straight-chain alkyl, and C1-C20 branched alkyl. In vitro experiments have verified that the sophoridine tricyclic derivative can inhibit TGF-β-induced activation of hepatic stellate cells, improve CCl4- and bile duct ligation-induced liver injury and liver fibrosis in mice, inhibit TGF-β / Smads signaling pathway activation, and also inhibit diethylnitrosamine-induced primary liver cancer in mice. Therefore, this invention provides new evidence for the treatment, alleviation, or improvement of liver fibrosis or primary liver cancer using sophoridine tricyclic derivatives.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN 18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses a traditional Chinese medicine compound for reducing the occurrence risk of liver cancer by improving a liver regeneration microenvironment and a preparation method of the traditional Chinese medicine compound. The traditional Chinese medicine compound is prepared by the following steps: adding water into five traditional Chinese medicine decoction pieces such as mistletoe, semen cuscutae, turmeric, oldenlandia diffusa and semen coicis, decocting twice (2 hours each time), combining decoctions, filtering, standing filtrate overnight, taking supernate, concentrating into thick extract, and storing the extract for later use; taking the thick paste, adding a proper amount of starch, uniformly stirring, putting into a drying box, and drying at the temperature of below 80 DEG C; taking out the dried product, weighing, crushing, adding starch until the total weight is 450g, and uniformly mixing for later use; taking the medicinal powder, preparing a soft material by using 80% ethanol, granulating, drying at the temperature of 80 DEG C or below, and finishing granules. And taking the granules, adding 0.3% of magnesium stearate, uniformly mixing, filling into No.0 capsules, preparing 1000 granules (0.45 g per granule), carrying out aluminum-plastic plate pressing, and packaging. The compound traditional Chinese medicine is mainly used for reducing the occurrence risk of liver cancer by improving the liver regeneration microenvironment for chronic liver disease patients.

The application belongs to the technical fields of synthesis of compounds and pharmaceutical applications, and discloses an anti-tumor pterostilbene piperazine conjugate as well as a preparation method and application thereof. The pterostilbene, piperazine and various substituents are spliced in one molecule by using a molecular hybridization method, a novel anti-tumor pterostilbene piperazine conjugate is synthesized, and it is found through anti-tumor activity research that the anti-tumor activity of the conjugate is obviously higher than that of the two pharmacophores alone, and the conjugate has the potential to become a novel anti-tumor drug. The pterostilbene piperazine conjugate is synthesized, and it is found for the first time that the compound has good anti-tumor activity, can significantly inhibit the proliferation of various tumor cells in vitro, including hepatocarcinoma, triple-negative breast cancer, colon cancer and ovarian cancer cells, has little toxicity to normal cells, and can inhibit the migration ability of tumor cells. Therefore, the compound synthesized by the application has good anti-tumor application prospect.

The invention discloses a functional small molecule peptide based on eggshell membrane peptide and application of the functional small molecule peptide in drug delivery, and belongs to the field of biological medicine. The invention relates to a functional small molecule peptide based on eggshell membrane peptide, which has pH responsiveness, can target liver cancer, can be prepared into a drug-loaded self-assembly body, and has a structural formula shown in Figure 1. The invention designs a novel small molecule peptide, develops a novel combined treatment scheme of a COX-2 inhibitor and a chemotherapeutic drug, and combines the anti-proliferation effect of DOX and the pro-apoptosis effect of CXB, so as to improve the therapeutic effect of the CXB. The activity of COX2 and the activation of hepatic stellate cells are inhibited, and the synergistic effect of resisting liver cancer is realized. Especially, the pH responsiveness of the experimental peptide Pep is utilized, morphology transformation occurs in a subacid environment, drug excretion and liver cancer proliferation are inhibited, and the functional small molecule peptide capable of enhancing the effect and reducing the toxicity provides a new treatment choice for liver cancer patients.

This application relates to an evaluation method and system in the quality control process of liver cancer. The method includes decomposing a set of received three-dimensional ultrasound contrast images according to connection points; grouping objects belonging to different three-dimensional ultrasound contrast images into the same comparison group, with objects in each comparison group generated based on the same structural tissue; sorting multiple objects in a comparison group according to generation time; comparing the degree of change of two adjacent objects belonging to the same comparison group in the time series, and statistically analyzing the number of objects whose degree of change exceeds the allowable degree of change, or calculating the ratio of the sum of the lengths of the parts of the objects whose degree of change exceeds the allowable degree of change to the sum of the lengths of all objects. This application provides an evaluation method and system in the quality control process of liver cancer, which achieves quantitative analysis of local images and provides a comparison of changes in treatment effects before and after treatment by using spatial decomposition and degree of change comparison, thereby providing data reference for subsequent liver cancer quality control processes.

This invention discloses a mixed hepatocyte terahertz quantitative detection system, electronic device, and medium, comprising: a spectral preprocessing module for acquiring a mixed hepatocyte time-domain spectrum and converting it into a mixed hepatocyte terahertz frequency-domain spectrum using a fast Fourier transform; calculating the refractive index and absorption coefficient to obtain frequency-domain signals of the refractive index and absorption coefficient, and processing them using Gram angle sum field and Gram angle difference field to obtain Gram angle sum field map and Gram angle difference field map; an image feature extraction module for extracting gradient features from the Gram angle sum field map and Gram angle difference field map using gradient histograms; extracting grayscale features from the Gram angle sum field map and Gram angle difference field map using grayscale histograms; fusing the gradient features and grayscale features to obtain image features; and a hepatocyte cancer cell content quantitative detection module for inputting the image features into a pre-trained hepatocyte cancer cell content quantitative detection model to obtain the proportion of hepatocyte cancer cells.

The application provides a method and device for recommending a hepatic cancer embolism placement point planning, wherein the method comprises the following steps: obtaining input data; segmenting the input data to obtain a segmentation result of the input data, and classifying the segmentation result to determine whether there is a high-risk tumor in the liver; if there is a high-risk tumor in the liver, calculating an embolism placement point according to the segmentation result, generating an embolism placement point planning result; synthesizing the embolism placement point planning result with an original medical image to generate a recommended scheme, and outputting the recommended scheme. Through deep learning, machine learning and traditional image processing methods, various organs such as patient arterial vessels, livers, tumors and bones are automatically segmented, and according to the automatically generated segmentation information, recommended information is generated to recommend the embolism placement point of each tumor, so as to assist doctors in comprehensively and deeply understanding the condition of the patient.

The invention relates to a bufalin derivative as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the invention, TEMPO oxidation reaction is adopted to selectively oxidize 19-site primary alcohol in 19-OH bufalin into aldehyde, so that 19-CHO bufalin is successfully synthesized, namely the bufalin derivative is obtained. The bufalin derivative has a remarkable killing effect on pancreatic cancer BxPC-3 cells, liver cancer HepG2 cells and brain glioma U-87MG cells, the IC50 of the bufalin derivative to the BxPC-3 cells is 40.63 nM, the IC50 of the bufalin derivative to the HepG2 cells is 36.74 nM, the IC50 of the bufalin derivative to the U-87MG cells is 28.73 nM, and the IC50 of the bufalin derivative to CHO-K1 cells is larger than 30 [mu] M, so that the bufalin derivative is relatively weak in toxicity to the heart, and the bufalin derivative has a remarkable killing effect on the liver cancer BxPC-3 cells, the liver cancer HepG2 cells and the brain glioma U-87MG cells. The compound can be applied to medicines for resisting pancreatic cancer, liver cancer and brain glioma.

Relates to a compound and application thereof in treatment of chronic hepatitis B, hepatic fibrosis and liver cancer. Specifically provided are compounds represented by formula O, or stereoisomers, prodrugs, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, # imgabs0 # of the compounds, or stereoisomers, prodrugs, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof

The present invention belongs to the field of medicine, and specifically relates to a Euphorbia licorice supramolecular hydrogel and a preparation method and use thereof. The supramolecular hydrogel comprises Euphorbia ethyl acetate extract and glycyrrhizic acid, and the Euphorbia ethyl acetate extract and the glycyrrhizic acid interact with each other to form nanoparticles by self-assembly. The preparation method of the Euphorbia licorice supramolecular hydrogel comprises the following steps: weighing the Euphorbia ethyl acetate extract and glycyrrhizic acid and placing them in a round-bottom flask, adding an appropriate amount of deionized water, and decocting for 0.5 to 2 hours. Experimental results show that the Euphorbia licorice supramolecular hydrogel of the present invention has a good anti-hepatoma ascites effect and has excellent safety compared with conventional chemotherapy drugs.

The application discloses a stable liver cancer embolism emulsion of raltitrexed drug gel and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The emulsion is composed of iodized oil embolism agent and raltitrexed drug gel; the raltitrexed drug gel is a nanofiber network hydrogel formed by self-assembly of raltitrexed molecules in an aqueous phase through ultrasonic treatment, and simultaneously serves as an active pharmaceutical ingredient and an emulsion stabilizer. The iodized oil and the raltitrexed drug gel are physically mixed and injected through a three-way valve to form a stable oil-in-water emulsion or a water-in-oil emulsion, and any additional chemical surfactant or cosolvent is not needed. The emulsion has excellent physical stability, and can effectively solve the problems of easy aggregation and sedimentation of a traditional iodized oil emulsion and increased systemic toxicity caused by drug burst release. The emulsion has good embolism effect and drug release behavior, can significantly inhibit tumor growth, and has a wide clinical transformation prospect.

The invention discloses a construction method of an in-vitro liver cancer liver invasion and metastasis experimental model, and relates to the technical field of model construction, and the construction method comprises the following steps: culturing liver cancer cells and hepatic stellate cells, carrying out fluorescence labeling, generating a space coordinate set by using the fluorescence labeled liver cancer cells and hepatic stellate cells, and calculating the in-vitro liver cancer liver invasion and metastasis experimental model. The method comprises the following steps of: printing liver cancer cells and hepatic stellate cells according to a space coordinate set to generate a three-dimensional cell-matrix structure, pouring photoresponse hydrogel into the three-dimensional cell-matrix structure, and inducing HOTAIR long non-coding RNA concentration by using a transforming growth factor to obtain the three-dimensional cell-matrix structure integrated with the photoresponse hydrogel. The space coordinate set is generated through the Markov model, accurate simulation of radial distribution of the highly invasive liver cancer cell core area and the hepatic stellate cells is achieved, and an accurate position template is provided for printing of a three-dimensional cell-matrix structure.

The invention relates to the field of medical instruments, in particular to a liver cancer diagnosis device based on the traditional Chinese medicine meridian theory. The problems that in the prior art, acupuncture point disinfection steps are complex, the pressing force of a detection probe is difficult to grasp, so that a patient feels uncomfortable, acupuncture point positioning is inaccurate, and signal collection is inaccurate are solved. According to the device, a coaxial cross positioning system is adopted, a positioning mechanism is composed of a base cross hollowed-out part, a cross supporting piece and a cross disinfection head, and accurate positioning is achieved in cooperation with acupuncture point marking. According to the disinfection mechanism, automatic switching between a probe and a cross disinfection head is achieved through a U-shaped hydraulic part, and the whole disinfection-detection process can be completed through single rotation of a rotary table. The magnetic buffering assembly provides progressive tactile feedback through repulsive force of homopolar magnets, and the optimal contact pressure of the probe is ensured through cooperation with a buffering spring. Signal acquisition adopts a differential layout formed by a core probe and an annular array bioelectric sensor. The operation convenience and the detection accuracy are remarkably improved, and a reliable solution is provided for modern diagnosis of traditional Chinese medicine.

The invention provides a small molecule nucleic acid drug for intervening in cancer specific LINC00942 and application of the small molecule nucleic acid drug in targeted therapy of liver cancer, and discovers a non-coding RNA LINC00942 with high expression in liver cancer and capable of promoting cancer length, and the non-coding RNA LINC00942 is used as a potential target for treating liver cancer. According to the present invention, the siRNA sequence specifically targeting LINC00942 is designed, and the siRNA sequence is coupled with the GalNAc ligand; the GalNAc can be combined with an ASGPR receptor which is specifically expressed on the surface of the hepatocyte, so that the siRNA conjugate is accurately delivered into the hepatocyte. According to the method, the problem of siRNA delivery is effectively solved, and specific silencing of LINC00942 is realized, so that the purpose of inhibiting growth of liver cancer cells is achieved. Besides, the invention provides a novel liver cancer treatment method, and the effect of targeted treatment of liver cancer is achieved by specifically silencing LINC00942 with high expression of liver cancer by using a GalNAc mediated siRNA delivery system.

The application discloses an alpha-linolenic acid and metal iridium coupling compound, a preparation method and application thereof, and relates to the field of medicine, in particular to an alpha-linolenic acid and metal iridium coupling compound, which has good antitumor activity on human cervical cancer cells, human hepatoma cells and mouse breast cancer cells. The preparation method is simple and easy to operate, and the product has good antitumor activity.

The invention relates to a compound and application thereof in treatment of chronic hepatitis B, hepatic fibrosis and liver cancer. Specifically provided are a compound represented by formula I, or a stereoisomer, a prodrug, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate of the compound,

The invention discloses a preparation method and application of a urea triazole derivative which is simple and easy to operate, cheap and easily available in raw materials, high in reaction efficiency and good in inhibition effect on human liver cancer cells Huh-7, and belongs to the technical field of medicine synthesis. According to the key points of the technical scheme, the urea triazole derivative molecule has a structure, or R1 is hydrogen atom, fluorine, chlorine, bromine, iodine, nitryl, alkyl (such as methyl, ethyl or alkynyl) or alkoxy (such as methoxyl) and various substituent groups, R2 is phenyl derivative or benzyl derivative, and X is oxygen atom or sulfur atom. The invention designs and synthesizes a urea triazole derivative with a novel structure, and the compound has a good inhibition effect on human liver cancer cells Huh-7.

To provide methods for effectively treating and / or preventing cancer diseases.SOLUTION: The present invention provides a combination therapy comprising an anti-Claudin (CLDN) 18.2 antibody and an immune checkpoint inhibitor for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.SELECTED DRAWING: Figure 1

The application belongs to the technical field of medicine, and relates to extraction and separation of a guaiane sesquiterpene glycoside compound guaiane sesquiterpene glycoside II from rhizome of rabdosia japonica by using macroporous resin, normal-phase silica gel, reverse-phase silica gel and dextran gel column chromatography and recrystallization and the like. 21 H 36 O8, in-vitro anti-tumor activity research shows that the compound has good anti-tumor activity, including obvious inhibition on human gastric cancer cells BGC-823, human hepatoma cells HepG-2 and human lung cancer cells A549. The application can provide a source of pharmacodynamic material basis for development of anti-tumor drugs, and has development and application prospects.

The application discloses a kind of nuclear magnetic resonance image prediction model construction methods, main design concept is in, from the information between using multi-stage liver cancer nuclear magnetic image data start to improve the prediction performance of the prediction model constructed, specifically, propose by multiple multilayer convolutional neural network as the extraction part of image feature, in this link, introduce multi-sequence image difference extraction pyramid module, difference information is mined between the input two two image stages and is integrated into image feature extraction operation, then the feature map containing difference information extracted by convolutional neural network is sent into multi-sequence image correlation attention module, learn the correlation between the input different stage nuclear magnetic image, and then provide rich reference information for subsequent accurate prediction classification.The present application can make full use of the difference information and correlation information between the images of different stages in the enhanced nuclear magnetic image, so as to effectively improve the prediction performance of the model based on image information.

The invention relates to the technical field of bioengineering, in particular to an LAG3 shear variant and application thereof. The nucleotide sequence of the splicing variant of the LAG3 provided by the embodiment of the invention is as shown in SEQ ID No. 1. Compared with an existing shear variant, the LAG3 new shear variant provided by the invention can better promote proliferation of a hepatoma cell line, and inhibition of expression of the LAG3 new shear variant can remarkably reduce growth of the hepatoma cell line, so that the specificity of a coding region of the LAG3 new shear variant has a wide application prospect in the aspects of diagnosis and treatment of hepatoma.